Disc Medicine, Inc.
NASDAQ:IRONBiotechnology
-$0.02 today
- Market cap
- $2.99B
- Beta
- 2.10
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$6.28
Volume 0.95M
Average 0.47M
IRON Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Disc Medicine, Inc.NASDAQ: IRON
Operating Expenses · Q3 FY2026 · quarter ended Sep 2026
Operating expenses dips below year-ago levels
Q3 FY2026 operating expenses of $64.16M fell 5.2% year over year, behind the +30.5% change in trailing-twelve-month operating expenses. Sequentially, it fell 1.4% from the prior quarter. Over 3 fiscal years it compounded at +70.7% a year.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -5.2% toward the trailing-twelve-month pace of +30.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 236.02M USD
- Year-over-year change
- +81.9%
- 4-year CAGR
- +66.2%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 236.02M | +81.9% |
| FY2024 | 2024-12-31 | 129.72M | +42.4% |
| FY2023 | 2023-12-31 | 91.13M | +91.9% |
| FY2022 | 2022-12-31 | 47.48M | +53.5% |
| FY2021 | 2021-12-31 | 30.93M | — |
Operating Expenses vs competitors
How IRON compares with its peers on the latest reported figures
- IRON's LTM Sep 2026 operating expenses of $265.73M is the 2nd highest of the 6 companies compared; the peer median is $223.24M.
- Its year-over-year change of +30.5% is the 2nd highest of 5, against a peer median of +16.6%.
- Over three fiscal years its annual growth of +70.7% compares with a peer median of +13.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $529.74M | +12.7% | +8.6% | 802.0% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $265.73M | +30.5% | +70.7% | — |
DMRADamora Therapeutics, Inc. | LTM Mar 2026 | $239.02M | +1655.8% | +51.4% | — |
| LTM Jun 2026 | $223.24M | +20.5% | +8.7% | 79.2% | |
| LTM Mar 2026 | $207.18M | -16.5% | +18.7% | 105.6% | |
COAGHemab Therapeutics Holdings, Inc. Common Stock | FY2025 | $70.12M | — | — | — |
| Peer median (excluding IRON) | $223.24M | +16.6% | +13.7% | 105.6% | |
Competitors are the stored peer set for IRON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 25.17M | 33.44M | 69.26M | 96.67M | 170.64M |
| Selling, General & Admin | 5.76M | 14.04M | 21.86M | 33.05M | 65.38M |
| Operating Expenses | 30.93M | 47.48M | 91.13M | 129.72M | 236.02M |
| Depreciation & Amortization | 32K | 89K | 100K | 156K | 281K |
| EBITDA | (33.78M) | (46.74M) | (76.23M) | (108.27M) | (207.94M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (30.93M) | (47.48M) | (91.13M) | (129.72M) | (236.02M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 14K | 709K | 14.8M | 21.29M | 27.76M |
| Interest Expense | 2.16M | 0 | 0 | 572K | 3.61M |
| Other Income / Expenses | (5.04M) | 648K | 14.8M | 20.72M | 24.2M |
| Income Before Tax | (35.97M) | (46.83M) | (76.33M) | (109M) | (211.82M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 99K | 355K | 361K |
| Net Income | (35.97M) | (46.83M) | (76.43M) | (109.36M) | (212.18M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (44.88) | (45.05) | (3.42) | (3.96) | (6.01) |
| EPS (Diluted) | (44.88) | (45.05) | (3.42) | (3.96) | (6.01) |
| Weighted Avg Shares | 801.47K | 1.04M | 22.32M | 27.61M | 35.3M |
| Weighted Avg Shares (Diluted) | 801.47K | 1.04M | 22.32M | 27.61M | 35.3M |
Disc Medicine, Inc.
NASDAQ:IRON
Intrinsic Alpha fair value
Locked
Current Price
$77.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.